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ABSTRACT
Bicuspid aortic valve disease is a common congenital cardiac disorder, being present in 1% to 2% of the general population. Associated aortopathy is a common
finding in patients with bicuspid aortic valve disease, with thoracic aortic dilation
noted in approximately 40% of patients in referral centers. Several previous
consensus statements and guidelines have addressed the management of bicuspid
aortic valve–associated aortopathy, but none focused entirely on this disease process. The current document is an executive summary of ‘‘The American Association for Thoracic Surgery Guidelines on Bicuspid Aortic Valve–Related
Aortopathy.’’ All major aspects of bicuspid aortic valve aortopathy, including natural history, phenotypic expression, histology and molecular pathomechanisms,
imaging, indications for surgery, surveillance, and follow-up, and recommendations for future research are contained within these guidelines. The current executive summary serves as a condensed version of the guidelines to provide
clinicians with a current and comprehensive review of bicuspid aortic valve aortopathy and to guide the daily management of these complex patients. (J Thorac
Cardiovasc Surg 2018;156:473-80)

Typical patient with BAV with associated aortopathy.
Central Message
The current document is an executive summary of ‘‘The
American Association for Thoracic Surgery Guidelines
on Bicuspid Aortic Valve–Related Aortopathy.’’

Perspective
BAV-related aortopathy is a common clinical entity. An
increasing amount of literature has recently shown that
BAV aortopathy is less dangerous than previously
described. The current Executive Summary is a
condensed version of the ‘‘American Association for
Thoracic Surgery Guidelines on Bicuspid Aortic
Valve–Related Aortopathy,’’ providing clinicians with a
current and comprehensive review of BAV aortopathy
and its management.
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INTRODUCTION
Bicuspid aortic valve (BAV) disease is the most common
congenital cardiac disorder, being present in 1% to 2% of
the general population.1 Associated aortopathy is a common finding in patients with BAV disease, with thoracic
aortic dilation noted in approximately 40% of patients in
referral centers. Several previous documents have addressed the management of BAV-associated aortopathy,
with one of the first being a set of multisocietal guidelines
published in 2010.2-8 Of these prior publications, none
focused entirely on patients with BAV aortopathy.
Therefore, the current Consensus Statement differs in that
it covers all major aspects of BAV aortopathy, including
its natural history, phenotypic expression, histology and
molecular pathomechanisms, imaging, indications for
surgery, surveillance and follow-up, and recommendations
for future research. It aims to provide clinicians with a current and comprehensive review of BAV aortopathy and to
guide the daily management of these complex patients.
The full Consensus Statement can be found online, and
the current document serves as its executive summary
(please see full-length document on pages e41-e74 in this
issue).
EPIDEMIOLOGY, PATHOPHYSIOLOGY, AND
CLINICAL PHENOTYPES
Contemporary clinical outcomes for patients with BAV
have been summarized in a comprehensive table by Michelena and colleagues9 from the International BAV Consortium (see Table 2 in the full-length document on pages
e41-e74 in this issue). These data show excellent overall
survival of patients with BAV in community, populationbased studies, whereas outcomes are not as good in patients
who have required aortic valve replacement (AVR). Heart
failure is particularly uncommon in patients with BAV,
and aortic stenosis is a more common indication for surgery
than aortic insufficiency. Thoracic aortic aneurysm
474
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formation (aortic diameter >45 mm) occurs in 25% to
45% of patients over prolonged periods of follow-up. However, aortic dissection is a rare event (1%) outside of tertiary referral center populations, in whom it is more
common (10%).9
The evidence of phenotypic heterogeneity of BAV aortopathy has emerged in the last decade from several observational studies and has stimulated a critical reappraisal of the
literature and treatment recommendations. The proposed
hypothesis is that different types of BAV aortopathy (ie,
so-called aortic phenotypes) may be caused by distinct
pathogenetic mechanisms and therefore require individualized surgical approaches.10,11 In particular, the 2 longdebated theories on BAV-aortopathy pathogenesis, namely,
the genetic and hemodynamic theories, could both be plausible inasmuch as different phenotypic forms might be variable expressions of both causative factors. Phenotypic
heterogeneity of BAV aortopathy also may explain some
of the inconsistencies in published natural history and
follow-up studies, especially regarding the risk of aortic
events in BAV disease. Previous data from mixed BAV cohorts resulted in a wide variety of suggested surgical treatments, ranging from very conservative approaches to very
aggressive recommendations, usually extrapolated from
guidelines for management of patients connective tissue
disorders (eg, Marfan syndrome).3 Clinicians’ thresholds
for surgical intervention of BAV-associated aortopathy
have been similarly diverse and sometimes inconsistent
with consensus opinion and guidelines.12
AORTIC IMAGING
Transthoracic echocardiography (TTE) is the recommended imaging modality for the initial assessment of the aortic
valve and thoracic aorta, including the assessment of hemodynamic aortic valve function13 (Table 1). If any part of the
aorta is dilated or complete examination of the aorta is not
possible by TTE, computed tomography (CT) or magnetic
resonance imaging (MRI) is recommended. Hemodynamic
aortic valve assessment also can be performed by MRI,
although TTE remains the gold standard. TTE assessment
of aortic valve function is usually sufficient, but transesophageal echocardiography should be performed in patients
with unexplained left ventricular dilation or dysfunction.
When evaluating the BAV aorta with echocardiography,
the entire thoracic aorta should be assessed: aortic root
(aortic annulus, sinuses of Valsalva and sinotubular junction), tubular ascending aorta (proximal, mid, and distal),
aortic arch, and descending thoracic aorta, including diameter and Doppler assessment for the presence of coarctation.
Echocardiography-derived aortic root diameters greater
than 40 mm should be verified by electrocardiogramgated CT or MRI (Table 1). Given that the sinuses can dilate
asymmetrically, all 3 sinus-to-commissure (or sinus-tosinus) dimensions should be measured.14 The choice

The Journal of Thoracic and Cardiovascular Surgery c August 2018

Adult: Aorta: AATS Consensus Guidelines

between CT and MRI is dependent on their availability, the
institutional expertise, and the age of the patient. Younger
patients (ie, aged <50 years) would benefit from MRI surveillance to avoid CT-associated radiation exposure.
Ideally, interval measurements should be performed with
the same imaging modality and same technique (ie,
electrocardiogram-gated), and compared side-by-side by
an experienced reader.13
Aortic Imaging Surveillance
In patients with initial aortic dilatation (root or tubular
ascending aorta 40-49 mm), the thoracic aorta should be reimaged at 12 months. If stability is confirmed, then reimaging can be performed every 2 or 3 years (Table 2). The first
interval repeat measurement may be performed at 6 months
before proceeding to yearly assessments, especially if other
risk factors such as aortic coarctation or family history of
dissection are present. In patients with more advanced
initial aortic dilatation (root or tubular ascending aorta 5054 mm), the thoracic aorta should be reimaged at least every
12 months (yearly). As opposed to Marfan syndrome in
which the aortic root is predominantly involved, the most
common segment involved in patients with BAV is the
tubular ascending aorta9 (60%-70% of BAV dilated aortas).
Aortic growth rates for the tubular ascending segment in
adults with BAV have recently been reported to range from
0.4 to 0.6 mm/y,15,16 whereas earlier studies demonstrated
maximal dilatation rates of 1 to 2 mm/y. Few patients are
observed to have a dilation rate greater than 2 mm/y15,16
Although these represent ‘‘artificially annualized’’ rates, it
remains unlikely that patients with BAV will dilate at
more than 3 mm/y. It is also important to note that an
interval diameter change of 1 or 2 mm is within the
margin of error by current imaging modalities. Therefore,
an interval dilatation of 3 mm or greater should be
considered clinically significant.6 Absolute echocardiographic baseline aorta diameters do not reliably predict
the rate of dilatation; thus, systematic interval imaging
follow-up is required regardless of baseline diameter. Previous AVR is more common in patients with BAV presenting
with aortic dissection, compared with patients with
tricuspid aortic valve (TAV) with dissection.17 Therefore,
continued interval monitoring of the unrepaired aorta
post-AVR is suggested when there is evidence of aortopathy
by surgical or radiologic examination.
SURGICAL MANAGEMENT
The most important clinical decision for patients with
BAV-associated aortopathy is the appropriate timing of surgical intervention. Optimally, surgery should be recommended as soon as the risk of watchful waiting exceeds the risk
of surgical intervention. Unfortunately, the precise time
point when this occurs is sometimes difficult to identify
because it is dependent on the individual patient, surgeon,

TABLE 1. Recommendations for initial imaging of the aorta in
patients with bicuspid aortic valve
Recommendation

Class/LOE

TTE is the initial imaging modality of choice for
assessment of the aortic valve and thoracic aorta in
patients with BAV.

I/C3,18

The entire thoracic aorta should be measured by TTE,
reporting each aortic segment separately in
millimeters: root (sinuses of Valsalva), sinotubular
junction, tubular ascending aorta (proximal, mid and
distal), arch and descending thoracic aorta. Maximum
diameter, regardless of location, should be reported.
Aortic coarctation should be ruled out with Doppler
evaluation of the descending thoracic aorta and
abdominal aorta.

I/C3,5,18

If TTE cannot visualize any aortic segment or any
segment measures 45 mm or aortic coarctation
cannot be ruled out, recommend assessment of the
entire thoracic aorta with ECG-gated cardiac MRA or
CTA.

I/C19,20

If a patient is undergoing cardiac surgery and root or
tubular ascending aorta measure 40-44 mm by TTE,
recommend assessment of the thoracic aorta with
MRA or CTA before surgery.

I/C17,19,20

If aortic coarctation is present, screening for cerebral
aneurysms is recommended.

I/B5

LOE, Level of evidence; TTE, transthoracic echocardiography; BAV, bicuspid aortic
valve; ECG, electrocardiogram; MRA, magnetic resonance angiography; CTA,
computed tomography angiography.

and treatment center. Prophylactic aortic repair is recommended to prevent catastrophic aortic complications, that
is, aortic dissection and rupture. Factors that should be
considered when recommending aortic repair include
maximum aortic diameter, presence of aortic risk factors
(ie, rate of aortic growth, aortic wall thickness, BAV phenotype, uncontrolled hypertension, family history of aortic
complications, or other aortic conditions such as coarctation
or connective tissue disorders), presence of surgical risk
factors (eg, advanced age, decreased left ventricular function, redo surgery), concomitant indications for cardiac surgery (most commonly aortic valvular stenosis or
insufficiency), and surgeon/team experience and expertise.
Indications for Aortic Repair in Patients With
Bicuspid Aortic Valve With Significant Aortic Valve
Dysfunction
For patients with BAV and valve dysfunction significant
enough to meet indications for aortic valve surgery,
concomitant ascending aortic replacement is reasonable
when the diameter exceeds 4.5 cm (Class IIa, level of evidence C in American Heart Association (AHA)/American
College of Cardiology (ACC) 2014 guidelines,4 European
Society of Cardiology (ESC) 2014 aortic guidelines,6
ESC valvular guidelines7) (Table 3). The incidence of aortic
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TABLE 2. Recommendations for interval monitoring imaging of the
aorta in patients with bicuspid aortic valve
Recommendation

Class/LOE
6,13,18

Interval imaging should be performed with the same
imaging technique and measurement method, and
compared side-by-side with previous study by an
expert in that imaging technique.

I/C

Interval aorta imaging recommendations apply to
patients with native BAV and those who have
undergone AVR, given that aorta complications may
occur in patients with BAV postsurgery.

I/B17,21

In patients with normal initial aortic diameters by TTE,
the thoracic aorta should be reimaged every 3 to 5 y.

I/C13,15

In patients with initial aortic dilatation (root or tubular
ascending aorta measure 40-49 mm), the thoracic
aorta should be reimaged at 12 mo. If stability is
confirmed, then reimaging can be performed every 2
or 3 y.

6,13,15,16

I/C

6,13,15

In patients with more advanced initial aortic dilatation
(root or tubular ascending aorta 50-54 mm), the
thoracic aorta should be reimaged at least every 12 mo
(yearly).

I/C

If thoracic aortic dilation (45 mm) noted by TEE is not
reproducible with CTA or MRA (ie,>2-mm difference
between modalities), then interval imaging follow-up
should be performed with MRA or CTA.

I/C13,18

LOE, Level of evidence; BAV, bicuspid aortic valve; AVR, aortic valve replacement;
TTE, transthoracic echocardiography; TEE, transesophageal echocardiography;
CTA, computed tomography angiography; MRA, magnetic resonance angiography.

dissection and other aortic catastrophes post-AVR is low,
particularly in patients with BAV with aortic stenosis.19,22
Most patients with BAV undergoing AVR do not require
complete aortic root replacement surgery. Indeed, the
incidence of aortic root dilation post-AVR in patients with
BAV is low, similar to the incidence in patients with TAV
disease.23-25 Root replacement is reasonable to consider in
patients with BAV undergoing AVR with an aortic root
diameter exceeding 4.5 cm.
The type of implanted valve at the time of AVR may influence the extent of aortic repair in patients with BAV. In
patients with moderate aortic root dilation who have opted
for a mechanical valve, complete root replacement may be
considered. However, isolated AVR is preferable in young
patients who have opted for a biological valve because of
the low risk of subsequent aortic root rupture/dissection23,25
and the increased technical difficulty associated with repeat
aortic root replacement surgery.26
Patients with bicuspid aortopathy and relatively normal
aortic cusps with good mobility can be considered for
valve-sparing aortic root replacement surgery (ie, David
operation) in select centers (Table 3). Valve-sparing aortic
root replacement in patients with BAV is technically challenging and should be performed by surgeons with substantial clinical experience in TAV patients. Aortic valve repair
476

TABLE 3. Recommendations for aortic repair in patients with
bicuspid aortic valve aortopathy
Recommendation
Repair of the ascending aorta/root is recommended
when the aortic diameter is 55 mm in patients
without risk factors.

Class/LOE
I/B13,20,39-41

Repair of the ascending aorta/root should be performed
when the aortic diameter is 50 mm in patients with
risk factors (ie, root phenotype or predominant aortic
insufficiency, uncontrolled hypertension, family
history of aortic dissection/sudden death, or aortic
growth >3 mm/y).

IIa/B13,20,39-41

Repair of the ascending aorta/root may be performed in
patients with an aortic diameter of 50 mm when
the patients are at low surgical risk and operated on
by an experienced aortic team in a center with
established surgical results.

IIb/C32,33

Concomitant repair of the ascending aorta/root should
be performed when the aortic diameter is 45 mm in
patients undergoing cardiac surgery.

IIa/B13,19,39,42

Repair of the aortic arch is recommended in patients
with an aortic arch diameter of 55 mm.

I/B36,43

Concomitant repair of the aortic arch should be
performed in patients undergoing cardiac surgery
with an aortic arch diameter of 50 mm.

IIa/C44

Concomitant repair of the aortic arch may be
performed in patients undergoing cardiac surgery
with an aortic arch diameter of 45 mm, provided
the patients are at low surgical risk and operated on
by an experienced aortic team with established
surgical results.

IIb/C45

It is recommended that patients undergoing elective
aortic arch repair be referred to an experienced aortic
team with established surgical results.

I/B37,38

LOE, Level of evidence.

has been applied in carefully selected patients with BAV.
Good midterm results for isolated aortic valve repair have
been demonstrated in expert hands.27,28 However, the lack
of long-term follow-up data and the increased technical
complexity of aortic valve repair in patients with BAV
have resulted in a lack of widespread adoption of these
techniques.
Indications for Aortic Repair in Patients With
Bicuspid Aortic Valve Without Significant Aortic
Valve Dysfunction
Current guidelines recommend intervention on the aorta
in patients with BAV without significant aortic valvular
dysfunction (ie, valvular dysfunction does not meet criteria
for surgical valve repair/replacement) if the maximal aortic
diameter exceeds 5.5 cm and patients do not have any highrisk characteristics (Table 3) (Class I, level B in AHA/ACC
guidelines3,4 and Class I, level C in ESC 2014 guidelines6).
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Such recommendations are based on the observation that
6.0 cm represents a definite inflection point in the risk of
aortic complications and that natural history studies demonstrating a definitively increased risk of such complications
in patients with BAV (in comparison with TAV) are debatable. Although Michelena and colleagues20 demonstrated
that patients with BAV have a higher risk of aortic dissection than the general population,20 it is unknown at what
aortic diameter these dissections tend to occur. It is also unknown whether a dilated BAV aorta is at greater risk than a
dilated TAV aorta. Further complicating the issue, it has
been observed that many patients with aortic dissection present with an aortic diameter of less than 5.5 cm.29,30 Despite
this finding, routine replacement of the ascending aorta in
patients with an aortic diameter of less than 5.5 cm is not
warranted because the size of the denominator is not
known (ie, ‘‘aortic size paradox’’).
Certain factors may increase the risk of aortic complications in patients with BAV and therefore lead to an earlier
recommendation for intervention. Current guidelines
recommend surgical intervention at an aortic diameter of
5.0 cm in patients with any of the following risk factors:
aortic coarctation, a family history of aortic dissection, or
rapid aortic growth (>3-5 mm/y). In the AHA/ACC 2014
valvular guidelines, this is a Class IIa, level of evidence C
recommendation,4 and in the ESC 2014 aortic guidelines,
this is a Class I, level C recommendation.6 Intervention at
lower aortic diameters also can be considered in patients
with small body surface area or stature, particularly if
they have Turner syndrome. An indexed aortic diameter
cutoff of greater than 2.75 cm/m231 or an aortic crosssectional area to height ratio of greater than 10 cm/m232
may be used to guide earlier surgical intervention in patients
with small stature. Earlier intervention is occasionally justified in patients with a strong preference for early surgery.
Finally, surgical repair may be performed at a lower
threshold (ie, 5.0 cm) if the patient has low operative risk
and the procedure is performed by an experienced operative
team with established results.2,3,32,33
These recommendations generally reflect a change toward a more conservative approach for BAV-associated
aortopathy when compared with previous guidelines, which
stated that such patients should be managed as aggressively
as those with connective tissue disorders.3 Studies published subsequent to these earlier guidelines have demonstrated that patients with BAV have a markedly lower risk
of aortic complication and aortic dilation than those with
Marfan syndrome, with aortic catastrophe rates that are
similar to rates in patients with TAV aneurysm.15,20,34,35 It
is possible that some patients with BAV with distinct
morphologic patterns of dilatation are at increased risk for
complications. A recent joint statement of clarification
was published to address the discrepancies in previously
published guidelines.8

Management of Aortic Arch
BAV disease and associated aortopathy have been the
topics of multiple guidelines and consensus statements,
but most do not address the aortic arch specifically. Neither
the 2010 ACC/AHA guidelines3 nor the ESC Guidelines6
discuss indications for aortic arch repair in patients with
BAV. The 2014 Canadian Cardiovascular Society Position
statement was the first to recommend a threshold of
5.5 cm for replacement of aortic arch aneurysm associated
with BAV.36
Indications for repair of the aortic arch should be no
different in the setting of BAV compared with TAV. If a patient with BAV presents for AVR and has an ascending
aortic aneurysm with a normal aortic diameter at the takeoff
of the innominate artery, ascending aortic repair without
arch intervention is recommended. If the aortic arch has a
diameter of greater than 45 mm at the innominate artery
takeoff, hemiarch replacement is reasonable in experienced
centers, with the understanding that operative mortality and
risk of stroke may be increased. Total arch replacement is
reasonable in patients with BAV undergoing AVR with a
mid-aortic arch diameter of 4.5 cm or greater as measured
orthogonally by volume-rendered, cross-sectional imaging
reconstructions. However, such pathology is rare and usually found in patients with BAV with other causes of aortic
arch dilation (eg, previous aortic coarctation repair or aortic
dissection, concomitant connective tissue disorder, Turner
syndrome). Patients with BAV requiring complex elective
aortic arch surgery should be referred to high-volume centers with established results.37,38

MEDICAL MANAGEMENT
Follow-up Aortic Imaging
Imaging of the aorta early after surgical correction is
aimed at detecting anastomotic leaks and pseudoaneurysms, as well as establishing a baseline for future comparisons. Electrocardiogram-gated cardiac CT may be
preferred to nongated CT angiography or TTE for early
postoperative surveillance, because echocardiography is
often limited by the presence of prosthetic aortic valves
and therefore may miss periannular or anastomotic dehiscence. In younger individuals (aged <50 years), however,
repeat CT examinations should be used with caution to
avoid the risk of radiation-induced malignancy. In such instances, MRI is preferable.
The interval at which repeat imaging is performed after
aortic surgery is often dictated by the extent of the initial
operation and whether areas of aortic dilatation were not addressed during the initial surgery. In the absence of residual
aortic dilation/pathology, it is reasonable to suggest that the
entire aorta be imaged by CT or MRI 1 year after replacement and then as directed by clinical circumstances or evidence of aortic dilatation/pathology from that point forward
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TABLE 4. Recommendations for postsurgical repair, medical
management, and watchful waiting
Recommendation

Class/LOE

Radiologic imaging (with CTA or MRA) may be
performed after aortic surgery to establish a
postrepair baseline.

IIb/C

Ongoing postoperative surveillance intervals
should be individualized on the basis of the
clinical, anatomic, and surgical features. In the
presence of residual aortic dilation/pathology, it
is reasonable to image the entire aorta every
3-5 y by CT or MRI after repair.

IIa/B6,13,15-17,21

MRI should be considered for repeat examinations
in an adolescent or in the adult population aged
<50 y.

IIa/B18

Treatment of hypertension is recommended
according to country- and region-specific
guidelines.
Beta-blockers and inhibitors of the reninangiotensin system should be considered for
blood pressure control based on evidence
extrapolated from connective tissue disease
populations. Nonpharmacologic approaches
(salt reduction, weight reduction) should be
advocated as part of blood pressure control
strategies.

I/C13,53-57

IIa/C13,53-55

Patients with aortic aneurysms that are at or near
surgical thresholds for correction should avoid
strenuous lifting, pushing, or straining that
would require a Valsalva maneuver.

IIa/C3,36,48,49,58

It is recommended to avoid heavy weight lifting or
competitive athletics involving isometric
exercise when the ascending aortic diameter is
>45 mm.

I/B3,36,48,49,58

Patients with BAV and dilated aorta should be
precluded from private driving if the ascending
aorta diameter is >6.0 and restricted from
commercial driving if the ascending thoracic
aorta diameter is >5.5 cm.

IIa/C36,47

It is recommended that prepregnancy evaluation
and postpregnancy management of women with
BAV with or without associated aortopathy be
performed by practitioners with expertise in the
management of pregnant women with heart
disease.

I/C59

First-degree relatives of patients with BAV should
undergo screening echocardiography.

IIa/B52

LOE, Level of evidence; CTA, computed tomography angiography; MRA, magnetic
resonance angiography; CT, computed tomography; MRI, magnetic resonance imaging; BAV, bicuspid aortic valve.

(Table 4). When possible, these studies should be performed
at the same institution using similar imaging techniques and
protocols to minimize variation.
478

Medical Management and Watchful Waiting
The medical management of patients with BAV
aortopathy who are under surveillance consists mainly of
blood pressure control, along with cardiovascular risk
reduction via pharmacologic and nonpharmacologic
measures. There are no randomized trials to help guide
decision making in this specific patient group. Treating
hypertension with beta-blockers or inhibitors of the
renin-angiotensin system has been suggested, however,
based largely on extrapolation from studies in the Marfan
syndrome literature.36,46 At the present time, there are no
data to support lower blood pressure thresholds for
patients with dilated aortas in the setting of BAV, and
therefore, country- and region-specific guidelines
for treatment of hypertension should be followed.
General counseling on nonpharmacologic approaches to
cardiovascular risk reduction should be part of watchful
waiting in patients with BAV aortopathy.
There are no specific recommendations regarding automobile driving in patients with BAV aortopathy in previously published guidelines. However, the Canadian
Medical Association has recommended that patients with
abdominal aortic aneurysm be precluded from driving
when the rupture risk exceeds 10% per year.36 On the basis
of the best available observational data, this threshold of
risk is exceeded for thoracic aortic aneurysms greater than
6.0 cm in the ascending aorta or arch and greater than
6.5 cm in the descending aorta. A lower threshold for
rupture risk is reasonable for patients performing commercial driving.36,47
Exercise prescription or restrictions should be individualized in patients with aortic aneurysms. Patients with
previously repaired aortic dissection should avoid strenuous
lifting, pushing, or straining that would require a Valsalva
maneuver.3,36,48,49 Strenuous strength training may be
dangerous for patients with BAV aortopathy, because
aortic dissection has been linked to weight lifting.49 The
proposed mechanism is transiently elevated blood pressure
associated with isometric exercise or Valsalva maneuver.48
Heavy weight lifting or competitive athletics involving
isometric exercise may trigger aortic dissection, and such
activities should be avoided in patients with moderately
dilated aortas (ie, >45 mm) or when there has been a
significant interval increase in size. However, individuals
with bicuspid aortopathy can (and should) undergo
aerobic or endurance exercise because these exercises are
beneficial for blood pressure lowering.50 If patients
want to engage in vigorous aerobic exercise, one might
consider performing a symptom-limited stress test to
ensure that the patient does not have a hypertensive
response to exercise. In patients with a normal bicuspid
valve and no associated dilated aorta, no exercise
restrictions are required.
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Family Screening
Most cases of BAV disease are sporadic, but familial
clustering is not uncommon. Genetic studies have suggested
an autosomal dominant pattern with incomplete penetrance
and variable expressivity as the likely mode of inheritance.51 Approximately 10% of first-degree relatives have
the disorder.52 Therefore, it is recommended that firstdegree relatives of patients with BAV are screened with
echocardiography.
CONCLUSIONS
BAV disease with associated aortopathy is a complex
condition with elusive genetics and controversial pathophysiology. By virtue of the high frequency of BAV disease
in the general population, cardiac specialists should be
familiar with current recommendations for assessment,
monitoring, and treatment of this disorder.
The current document is an executive summary of a
larger consensus statement that covers all major aspects
of BAV aortopathy, including its natural history, phenotypic
expression, histology and molecular pathomechanisms, imaging, indications for surgery, surveillance, and follow-up,
and recommendations for future research (please see fulllength document on pages e41-e74 in this issue). Detailed
recommendations are found in Tables 1 to 4
accompanying this executive summary, which are meant
to serve as a guide to assist clinicians with the daily
management of these complex patients.
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